{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:51:24Z","timestamp":1773982284493,"version":"3.50.1"},"reference-count":155,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>In the last decade, antibody-drug conjugates (ADCs), normally formed by a humanized antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged as a potential treatment strategy in cancer disease. They allow to get a selective delivery of the chemotherapeutic agents at the tumor level, and, consequently, to improve the antitumor efficacy and, especially to decrease chemotherapy-related toxicity. Currently, nine antibody-drug conjugate-based formulations have been already approved and more than 80 are under clinical trials for the treatment of several tumors, especially breast cancer, lymphomas, and multiple myeloma. To date, no ADCs have been approved for the treatment of gynecological formulations, but many formulations have been developed and have reached the clinical stage, especially for the treatment of ovarian cancer, an aggressive disease with a low five-year survival rate. This manuscript analyzes the ADCs formulations that are under clinical research in the treatment of gynecological carcinomas, specifically ovarian, endometrial, and cervical tumors.<\/jats:p>","DOI":"10.3390\/pharmaceutics13101705","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:05:47Z","timestamp":1634511947000},"page":"1705","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0707-9810","authenticated-orcid":false,"given":"Cristina","family":"Mart\u00edn-Sabroso","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Lozza","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-6177","authenticated-orcid":false,"given":"Ana Isabel","family":"Torres-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-305X","authenticated-orcid":false,"given":"Ana Isabel","family":"Fraguas-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ygyno.2020.03.015","article-title":"Gynecologic cancer in pregnancy","volume":"157","author":"Korenaga","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2174\/0929867327666200819115403","article-title":"Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research","volume":"28","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","article-title":"Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment","volume":"137","author":"Kurnit","year":"2021","journal-title":"Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijrobp.2020.09.016","article-title":"Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation","volume":"109","author":"Dyer","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in Ovarian Cancer: Are We There Yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Peters, C., and Brown, S. (2015). Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep., 35.","DOI":"10.1042\/BSR20150089"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/0929867324666170817152554","article-title":"Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations","volume":"26","author":"Kholodenko","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/GCO.0000000000000515","article-title":"Antibody-drug conjugates for ovarian cancer: Current clinical development","volume":"31","author":"Stewart","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H.K., and Scott, A.M. (2020). Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25.","DOI":"10.3390\/molecules25204764"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1758835920915980","DOI":"10.1177\/1758835920915980","article-title":"Novel antibody-drug conjugates for triple negative breast cancer","volume":"12","author":"Nagayama","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40262-017-0619-0","article-title":"Antibody-Drug Conjugates: Pharmacokinetic\/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned","volume":"57","author":"Hedrich","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e12070","DOI":"10.1002\/jev2.12070","article-title":"Extracellular vesicles as modifiers of antibody-drug conjugate efficacy","volume":"10","author":"Barok","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"ref_16","unstructured":"Greenblatt, K., and Khaddour, K. (2021). Trastuzumab. StatPearls, StatPearls Publishing LLC."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the Treatment of Breast Cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"ref_19","unstructured":"Gandhi, T., and Bhatt, H. (2021). Cancer Antigen 125. StatPearls, StatPearls Publishing LLC."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/carcin\/bgab010","article-title":"The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia","volume":"42","author":"Giamougiannis","year":"2021","journal-title":"Carcinogenesis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14712598.2021.1869210","article-title":"Novel mesothelin antibody-drug conjugates: Current evidence and future role in the treatment of ovarian cancer","volume":"21","author":"Mauricio","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.33433","article-title":"Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"key":"ref_23","first-page":"293","article-title":"Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer","volume":"21","author":"Menderes","year":"2016","journal-title":"Discov. Med."},{"key":"ref_24","first-page":"39","article-title":"Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it","volume":"26","author":"Menderes","year":"2018","journal-title":"Discov. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bcp.12044","article-title":"Drug-conjugated antibodies for the treatment of cancer","volume":"76","author":"Lambert","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ferragut, F., Vachetta, V.S., Troncoso, M.F., Rabinovich, G.A., and Elola, M.T. (2021). ALCAM\/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression. Cytokine Growth Factor Rev.","DOI":"10.1016\/j.cytogfr.2021.07.001"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hagerty, B.L., Pegna, G.J., Xu, J., Tai, C.H., and Alewine, C. (2020). Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 10.","DOI":"10.3390\/biom10070973"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2018-CT036","article-title":"Abstract CT036: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study","volume":"78","author":"Moore","year":"2018","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","article-title":"Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody\u2013drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer","volume":"27","author":"Liu","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/PAI.0b013e318228e232","article-title":"In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35","volume":"20","author":"Soares","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"vi570","DOI":"10.1093\/annonc\/mdw435.29","article-title":"A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)","volume":"27","author":"Sachdev","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1538-7445.AM2018-754","article-title":"Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs\u2014A controlled bystander effect","volume":"78","author":"Clardy","year":"2018","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: A Novel Antibody\u2013Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/1078-0432.CCR-15-0695","article-title":"Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions","volume":"21","author":"Damelin","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.jsb.2020.107512","article-title":"Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity","volume":"211","author":"Hayashi","year":"2020","journal-title":"J. Struct. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"NT-090","DOI":"10.1158\/1557-3265.OVCASYMP18-NT-090","article-title":"Abstract NT-090: Preclinical Activity And Safety Of Stro-002, A Novel Adc Targeting Folate Receptor Alpha For Ovarian And Endometrial Cancer","volume":"25","author":"Abrahams","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","article-title":"MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FR\u03b1 Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity","volume":"17","author":"Cheng","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-Drug Conjugates for Cancer Treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.clbc.2020.08.006","article-title":"Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer","volume":"21","author":"Andrikopoulou","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab Deruxtecan: First Approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab Govitecan: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2019.02.017","article-title":"Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan","volume":"167","author":"Dong","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2326-6066.CIR-13-0007","article-title":"Radretumab radioimmunotherapy in patients with brain metastasis: A 124I-L19SIP dosimetric PET study","volume":"1","author":"Poli","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.hoc.2018.07.014","article-title":"Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer","volume":"32","author":"Richardson","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: An emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Abawi, A., Wang, X., Bompard, J., B\u00e9rot, A., Andretto, V., Gudimard, L., Devillard, C., Petiot, E., Joseph, B., and Lollo, G. (2021). Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084103"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-62703-541-5_4","article-title":"Antibody-drug conjugate payloads","volume":"1045","author":"Anderl","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dan, N., Setua, S., Kashyap, V.K., Khan, S., Jaggi, M., Yallapu, M.M., and Chauhan, S.C. (2018). Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020032"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jat.3582","article-title":"Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings","volume":"38","author":"Taplin","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00280-019-03844-z","article-title":"SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4","volume":"84","author":"Wong","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.2147\/IJN.S158426","article-title":"SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: In vitro and in vivo study","volume":"13","author":"Fang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4062\/biomolther.2015.116","article-title":"Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics","volume":"23","author":"Kim","year":"2015","journal-title":"Biomol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1021\/acs.bioconjchem.5b00399","article-title":"Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists","volume":"26","author":"Gordon","year":"2015","journal-title":"Bioconjug Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2019.03.021","article-title":"Antibody-drug conjugates- stability and formulation","volume":"139","author":"Duerr","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejmech.2014.08.062","article-title":"Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates","volume":"88","author":"Albers","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Chen, H., Lin, Z., Arnst, K.E., Miller, D.D., and Li, W. (2017). Tub.bulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules, 22.","DOI":"10.3390\/molecules22081281"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Nicolaou, K.C., Rigol, S., Pitsinos, E.N., Das, D., Lu, Y., Rout, S., Schammel, A.W., Holte, D., Lin, B., and Gu, C. (2021). Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2107042118"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/13543784.2020.1792443","article-title":"Trastuzumab-deruxtecan: An investigational agent for the treatment of HER2-positive breast cancer","volume":"29","author":"Bartsch","year":"2020","journal-title":"Expert Opin. Investig Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_73","first-page":"567","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates","volume":"43","author":"Singh","year":"2016","journal-title":"J. Pharm. Pharm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"118914","DOI":"10.1016\/j.lfs.2020.118914","article-title":"Nanotechnology in ovarian cancer: Diagnosis and treatment","volume":"266","author":"Barani","year":"2021","journal-title":"Life Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7150\/jca.49406","article-title":"Current Ovarian Cancer Maintenance Strategies and Promising New Developments","volume":"12","author":"Gogineni","year":"2021","journal-title":"J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102040","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2018.10.046","article-title":"Quality improvement in gynecologic oncology: Current successes and future promise","volume":"152","author":"Kumar","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Manzano, A., and Oca\u00f1a, A. (2020). Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12082223"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_82","first-page":"617","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"Matulonis","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"viii339","DOI":"10.1093\/annonc\/mdy285.157","article-title":"949P\u2014Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study","volume":"29","author":"Matulonis","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/j.annonc.2020.08.972","article-title":"833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer","volume":"31","author":"Richardson","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: Primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.7150\/thno.44334","article-title":"The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by (89)Zr-immuno-PET in xenograft bearing mice","volume":"10","author":"Chomet","year":"2020","journal-title":"Theranostics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2020.38.15_suppl.526","article-title":"CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC)","volume":"38","author":"Boni","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody\u2013Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_95","first-page":"A154","article-title":"372\u2005Safety and activity of the anti-mesothelin antibody\u2013drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","volume":"30","author":"Santin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.semcancer.2019.12.024","article-title":"Antibody-drug conjugates for lung cancer in the era of personalized oncology","volume":"69","author":"Ricciuti","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0039-1687894","article-title":"Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis","volume":"45","author":"Hisada","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_99","first-page":"1","article-title":"Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes","volume":"7","author":"Koizume","year":"2015","journal-title":"Biomark. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2013.09.016","article-title":"Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk","volume":"132","author":"Norris","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"Concin","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1535-7163.MCT-18-0537","article-title":"Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer","volume":"18","author":"Quinn","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_103","unstructured":"Chopra, A. (2004). (213)Bi\/(211)At-Labeled MX35, an anti\u2013sodium-dependent phosphate transport protein 2b (NaPi2b) murine monoclonal antibody, Molecular Imaging and Contrast Agent Database (MICAD)."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","article-title":"Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer","volume":"26","author":"Gerber","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdy023","article-title":"Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","volume":"29","author":"Banerjee","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2020.05.039","article-title":"Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer","volume":"158","author":"Moore","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_107","first-page":"7881","article-title":"PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Maitland, M.L., Sachdev, J.C., Sharma, M.R., Moreno, V.V., Boni, V., Kummar, S., Stringer-Reasor, E., Lakhani, N., Moreau, A.R., and Xuan, D. (2021). First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-20-3757"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2020.06.109","article-title":"A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation","volume":"159","author":"Richardson","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1016\/j.annonc.2020.08.975","article-title":"836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate","volume":"31","author":"Hamilton","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1039\/D1OB01077H","article-title":"Structural and mechanistic insight into DNA bending by antitumour calicheamicins","volume":"19","author":"Mills","year":"2021","journal-title":"Org. Biomol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmch.2018.12.002","article-title":"Chapter One\u2014Covalent binders in drug discovery","volume":"Volume 58","author":"Witty","year":"2019","journal-title":"Progress in Medicinal Chemistry"},{"key":"ref_113","first-page":"1","article-title":"Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates","volume":"4","author":"Adhikari","year":"2021","journal-title":"Antib. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/ijc.32154","article-title":"First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors","volume":"145","author":"Krop","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2020.05.038","article-title":"Tamrintamab pamozirine (SC-003) in patients with platinum-resistant\/refractory ovarian cancer: Findings of a phase 1 study","volume":"158","author":"Hamilton","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"10412","DOI":"10.3390\/ijms140510412","article-title":"Claudins overexpression in ovarian cancer: Potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy","volume":"14","author":"English","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"CT124","DOI":"10.1158\/1538-7445.AM2020-CT124","article-title":"Abstract CT124: First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6\/9, in patients with epithelial ovarian cancers","volume":"80","author":"Hamilton","year":"2020","journal-title":"Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"23045","DOI":"10.1002\/anie.202010090","article-title":"Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics","volume":"59","author":"Charoenpattarapreeda","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2016.06.010","article-title":"Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth","volume":"113","author":"Lai","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"CT125","DOI":"10.1158\/1538-7445.AM2020-CT125","article-title":"Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FR\u03b1) antibody drug conjugate (ADC), in patients with advanced platinum-resistant\/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers","volume":"80","author":"Naumann","year":"2020","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-\u03b1-Positive Advanced Solid Tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3322\/caac.21561","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pop.2018.10.011","article-title":"Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management","volume":"46","author":"Stumbar","year":"2019","journal-title":"Prim. Care"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijgo.12611","article-title":"Cancer of the cervix uteri","volume":"143","author":"Bhatla","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1080\/14656566.2019.1654996","article-title":"Systemic therapy for the treatment of endometrial cancer","volume":"20","author":"Neri","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/ijgc-2020-001822","article-title":"Adjuvant therapy for endometrial cancer in the era of molecular classification: Radiotherapy, chemoradiation and novel targets for therapy","volume":"31","author":"Horeweg","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Eiger, D., Agostinetto, E., Sa\u00fade-Conde, R., and de Azambuja, E. (2021). The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers, 13.","DOI":"10.3390\/cancers13051015"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Nadal-Serrano, M., Morancho, B., Escriv\u00e1-de-Roman\u00ed, S., Bernad\u00f3 Morales, C., Luque, A., Escorihuela, M., Espinosa Bravo, M., Peg, V., Dijcks, F.A., and Dokter, W.H.A. (2020). The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers, 12.","DOI":"10.3390\/cancers12030670"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"113803","DOI":"10.1016\/j.addr.2021.05.013","article-title":"Evolution of Toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants","volume":"175","author":"Bhagchandani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist. Updat."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1535-7163.MCT-17-0930","article-title":"In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers","volume":"17","author":"Altwerger","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbrc.2017.08.015","article-title":"Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1\/2\/c-Fos\/c-Jun","volume":"491","author":"Liu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Rinnerthaler, G., Gampenrieder, S.P., and Greil, R. (2019). HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int. J. Mol. Sci., 20.","DOI":"10.20944\/preprints201902.0043.v1"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2020.38.15_suppl.1049","article-title":"A first in-human study of A166 in patients with locally advanced\/metastatic solid tumors which are H.HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies","volume":"38","author":"Liu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_139","first-page":"2921","article-title":"HER-2\/neu overexpression and hormone dependency in endometrial cancer: Analysis of cohort and review of literature","volume":"25","author":"Mariani","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Wolber, P., Nachtsheim, L., Hoffmann, F., Klu\u00dfmann, J.P., Meyer, M., von Eggeling, F., Guntinas-Lichius, O., Quaas, A., and Arolt, C. (2021). Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target. Head. Neck. Pathol.","DOI":"10.1055\/s-0041-1728932"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Liu, T., Liu, Y., Bao, X., Tian, J., Liu, Y., and Yang, X. (2013). Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075864"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.gore.2018.05.009","article-title":"Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report","volume":"25","author":"Han","year":"2018","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Zhang, L., Kwan, S.Y., Wong, K.K., Solaman, P.T., Lu, K.H., and Mok, S.C. (2020). Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12030686"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Yao, H.P., Zhao, H., Hudson, R., Tong, X.M., and Wang, M.H. (2021). Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov. Today, 26.","DOI":"10.1016\/j.drudis.2021.06.012"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.drudis.2020.11.020","article-title":"How can the potential of the duocarmycins be unlocked for cancer therapy?","volume":"26","author":"Jukes","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ygyno.2017.04.023","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2\/Neu expression","volume":"146","author":"Menderes","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1535-7163.MCT-16-0163","article-title":"SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody\u2013Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2\/Neu Expression","volume":"15","author":"Black","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.det.2019.05.003","article-title":"Nonsurgical Treatments for Nonmelanoma Skin Cancer","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_155","first-page":"A244","article-title":"401\u2005Phase 1\/2 study of novel HER2-targeting, TLR7\/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors","volume":"8","author":"Sharma","year":"2020","journal-title":"J. ImmunoTher. Cancer"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:15:54Z","timestamp":1760166954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":155,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["pharmaceutics13101705"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13101705","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}